ohmx.bio

OHMX.Bio provides a complete R&D platform to help customers resolve their biological questions through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics. Current flagships in portfolio are ribosome profiling and third generation sequencing. With its in-house developed high performant ribosome profiling service, OHMX.bio provides a genome-wide assessment of mRNA targeted by translating ribosomes. This highly sensitive sequencing-based technology unravels the translatome, a snapshot of RNA that is being translated. Quantification of gene-specific translation, discovery of non-canonical translation events, investigation of ribosome elongation speed and pausing, figuring out translation regulation by microRNAs and RNA-binding proteins and/or determination of mechanisms related to translation initiation and termination, are made possible. OHMX.bio also services third generation sequencing workflows based on the Oxford Nanopore Technology. Direct DNA and RNA solutions allow for amplification-free sequencing of (ultra-)long reads and additionally allow to map their epigenetic features. Applications are everywhere, in the fields of clinical and more specifically cancer research, environmental and plant research, microbiology and microbiome analysis, genome and transcriptome research.

Hyloris Pharmaceuticals

We are a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. We have built a broad proprietary pipeline of complex value-added reformulated and repurposed products that have the potential to offer significant advantages over currently available medications. Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com.

adx neurosciences

Lab Tech Support

Lab Tech Support helps scientists and laboratory analysts increase uptime, research & testing all while decreasing maintenance and repair cost of analytical instrumentation. Laboratory Service Provider with 20+ years of experience in mass spectrometry repair, maintenance and support. Whether your are located in the United States, Canada, Mexico, or Europe, our Service Engineers are available 24/7!

nova biologics, inc.

NOVA Biologics, Inc. is a global provider of biologic raw material intermediates to clinical laboratories, research organizations, and pharmaceutical and in-vitro manufacturers. We offer a range of serums and plasma, including disease state and patient sample materials. As well as human and animal-derived products for use in cell culture, IVD, and further manufacture of therapeutic injectable products. Nova Biologics, Inc. is dedicated to providing the highest quality biologic raw material intermediates to our diverse customer base in order to help meet the demanding needs and requirements of their organizations. We are committed to establishing strategic, long-term relationships with our valued customers and partners by providing them with secure procurement of products at competitive prices in a timely manner. Our vision is to continue to facilitate supply and manufacturing partnerships allowing NOVA to expand our product and service capabilities. Our products include diagnostic serums and plasma, human serum albumin, human gamma globulin, disease plasmas, clinical samples, and human and animal-based materials. Nova is the sales representative for Octapharma excipient albumin to the biotech and pharmaceutical industry worldwide.